search

Active clinical trials for "Hemophilia A"

Results 501-510 of 769

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing...

Haemophilia B

The main objective of the study is to investigate the safety and efficacy of Replenine®-VF administered by continuous infusion in appropriate dosage to prevent bleeding and achieve haemostasis in patients with haemophilia B undergoing major surgery.

Completed2 enrollment criteria

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d)...

Hemophilia A

This study hypothesizes that the study drug, PF-05280602 (at the selected doses) will be safe to administer to subjects with severe Hemophilia A or B with or without inhibitors and will demonstrate evidence of hemostatic activity. This is supported by the preclinical findings in hemophilic animal models.

Completed6 enrollment criteria

Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived...

Hemophilia B

The purpose of this study is to collect data around the period of the conversion from plasma-derived Factor IX (pdFIX) to BeneFIX. The main information collected will be: a retrospective history of the bleedings in the 3-month period before the conversion, the recovery with pdFIX just before the conversion and with BeneFIX just after the conversion, and a prospective history of the bleedings in the 3 month period following the conversion.

Completed15 enrollment criteria

Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay...

Hemophilia A

A novel immuno-assay is being evaluated for the measurement of Factor VIII. Current procedure measures a rate assay which is subject to much artefact. The hypothesis is that the new assay will give a reading of absolute quantities of FVIII which will provide a more suitable indicator of FVIII content for clotting factor manufacturers, physicians and patients.

Completed5 enrollment criteria

Lentiviral FVIII Gene Therapy

Hemophilia A

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Unknown status12 enrollment criteria

A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines...

Hemophilia AFactor VIII Deficiency3 more

The purpose of this research study is to see if factor levels and inhibitor levels in Hemophilia A and B subjects are accurate when they are drawn from a central venous line (CVL) instead of from a peripheral stick.

Terminated3 enrollment criteria

Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A

Hemophilia A

In this trial safety and efficacy of SCT800 (B-domain deleted recombinant factor VIII) is being evaluated in 50 subjects, 12 to 65 years of age, with moderate to severe Hemophilia A. These subjects will receive open label treatment with SCT800 for approximately 6 months for on-demand treatment.

Unknown status20 enrollment criteria

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia...

Acquired Hemophilia A

The purpose of this prospective study is to determine the efficacy and safety of Rituximab plus Bortezomib in patients with newly diagnosed acquired hemophilia A.

Unknown status13 enrollment criteria

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

This study will assess the pharmacokinetics and pharmacodynamics of STSP-0601 at five dose levels. The results will help identify the most optimal doses to treat bleedings in hemophilia patients with inhibitors.

Unknown status16 enrollment criteria

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq

Hemophilia A

Uncontrolled, multi-centre, non-interventional study with a prospective and a retrospective cohort, to evaluate the efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in severe and moderate haemophilia A patients with inhibitors

Terminated17 enrollment criteria
1...505152...77

Need Help? Contact our team!


We'll reach out to this number within 24 hrs